Abstract

Exelixis will report second-quarter 2026 results on August 05, 2026 Post Market; this preview compiles last quarter’s actuals and the company’s current-quarter forecasts, alongside recent institutional commentary and media coverage within the period from January 29, 2026 to July 29, 2026.

Market Forecast

Based on the company’s guidance set and consensus indications, Exelixis’s current quarter is projected to deliver revenue of 0.64 billion US dollars, with an expected year-over-year growth of 10.71%, EBIT of 0.26 billion US dollars with 30.84% growth, and EPS of 0.79 with 40.59% growth. The main business is expected to remain anchored by net product revenue and collaboration services; momentum is anticipated to stem from sustained demand for the lead oncology franchise and steady contribution from partnered milestones. The segment with the most promise is net product revenue at an estimated scale consistent with prior quarter trends and supported by low double-digit year-over-year growth.

Last Quarter Review

In the previous quarter, Exelixis reported revenue of 0.61 billion US dollars, a gross profit margin of 96.73%, GAAP net profit attributable to shareholders of 0.21 billion US dollars, a net profit margin of 34.46%, and adjusted EPS of 0.79, with revenue up 9.97% year over year and adjusted EPS up 43.64% year over year. The company delivered better-than-expected profitability as operating leverage improved and expenses were contained relative to revenue growth. Main business performance was led by net product revenue of 0.55 billion US dollars and collaboration services of 0.06 billion US dollars, with net product revenue posting solid year-over-year gains.

Current Quarter Outlook (with major analytical insights)

Main business: Net product revenue trajectory

Net product revenue remains the core earnings driver this quarter, with forecast revenue growth in the low double digits and continued strong gross margin near prior levels. The combination of stable demand in core oncology indications and broader treatment adoption is likely to underpin sequential consistency. Price discipline and payer coverage appear supportive for sustaining high margins, which should translate into solid operating income conversion if operating spending stays in line with plan.

Most promising business: Net product expansion and lifecycle work

Among operating lines, net product revenue offers the clearest upside, leveraging the sizable installed prescriber base and incremental utilization in later-line settings. Expansion of treatment duration and patient retention trends support revenue durability, which, together with potential label or practice-pattern evolution, can add mid-teens growth tailwinds over a multi-quarter horizon. While collaboration services contribute, they remain a smaller share and tend to be milestone-driven, introducing variability that is less dependable than the primary product revenue stream.

Stock price swing factors this quarter

Share performance is likely to be most sensitive to the magnitude of revenue growth versus the ~10% year-over-year baseline and any updates to operating expense guidance that affect EBIT leverage. Any deviation in gross margin from the prior 96.73% run-rate would have an amplified impact on profitability, given the high fixed-cost absorption dynamics. Additionally, commentary on demand trends within key oncology settings and visibility into second-half revenue cadence will set expectations for EPS trajectory and valuation into year-end.

Analyst Opinions

The majority of recent institutional commentary tilts constructive on Exelixis’s near-term setup, emphasizing durable net product momentum, high gross margin quality, and improving EBIT leverage into the second half. Positive views center on the company’s ability to translate low double-digit top-line growth into faster EPS expansion, as reflected in the 30.84% EBIT and 40.59% EPS growth forecasts for the quarter. Analysts highlight that visibility on net product demand provides confidence in achieving mid-year targets, while variability from collaboration services is not expected to derail the earnings algorithm this quarter.